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T he drug-eluting balloon is a promising device to address the unmet needs of the current treatment of cardiovascular disease through catheters. In 
Europe, drug-eluting balloons from several manufacturers 
have been approved for use in clinical practice, and 
abundant evidence on the treatment of both peripheral 
vascular disease and coronary artery disease has been 
published.1,2
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There are three important components in drug-
eluting balloon technology. One is the drug, the other 
is the balloon catheter, and the last is the excipient 
that binds the drug to the balloon catheter surface and 
releases it to the vessel wall. It is a surprising fact that 
all drug-eluting balloons currently approved in Europe 
use the same drug (paclitaxel), unlike the situation with 
drug-eluting stents, as most stents use drugs from the 
‘limus family’. Paclitaxel is an antiproliferative and lipo-
philic drug, and it is believed that these features allow 
for rapid infiltration and cell proliferation suppres sion.3 
Considering that sirolimus in drug-eluting stents has 
a more potent antiproliferative effect than paclitaxel,4 
sirolimus may be beneficially used for local release 
of the drug in association with the balloon catheter. 
Both drugs are hydrophobic, and it is natural to expect 
them to have similar release patterns. Furthermore, it is 
expected that the excipient will be further improved. 
This component, perhaps, is the key component of 
drug-eluting balloons, as the other two components 
are the same in all balloons, and it may differentiate 
them regarding their efficiency.
In the study published by Takimura et al.5 in this issue 
of Revista Brasileira de Cardiologia Invasiva, the authors 
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tested a new drug-eluting balloon using sirolimus instead 
of paclitaxel in a preclinical study. Although several groups 
are currently testing drugs from the ‘limus family’ in drug-
eluting balloons in preclinical studies,6,7 no balloon that 
uses sirolimus has been approved for use in daily practice. 
As their clinical efficacy is yet to be clearly established, 
the industry cannot take the risk of making large expen-
ditures on research and development with a well-known 
drug in drug-eluting stents; thus, the companies tend to 
select a ‘me-too’ drug*, such as paclitaxel.
In the study by Takimura et al.,5 a single excipient is 
used to release sirolimus. This device uses synthetic nanopar-
ticles and consists of a double phospholipid membrane that 
contains sirolimus. In previously published data, in vitro 
tests showed both stable adhesion of the balloon coating 
and a smooth, uniform and regular surface, without folds 
or fractures.8,9 Furthermore, in sirolimus-coated balloons, 
after brief exposure to the arterial wall of 60 seconds, 
these nanoparticles were initially found on the endothelial 
surface, followed by the middle layer and, finally, deeper 
layers, such as the adventitia.10 The method of drug deliv-
ery by nanoparticles is relatively new, but several groups 
have tested nanoparticles in drug-eluting devices used 
in cardiovascular interventionist treatment.11,12 To test the 
clinical relevance of this new technology in drug-eluting 
balloons after bench testing, the next step will be to study 
their efficacy in preclinical trials.
Takimura et al.5 successfully demonstrated the 
efficacy of this new drug-eluting balloon using siro-
limus and nanoparticles in different excipient:drug 
formulations through optical coherence tomography 
and histopathology in a healthy porcine model. Dose 
dependence was observed regarding the effectiveness of 
neointimal proliferation inhibition, with little inflammation 
or damage as the excipient concentration increased.5 
* Pharmacology – A popular term for a generic drug with an identical formulation and stated indications as a previously FDA-approved agent; MTDs 
are usually approved ‘automatically’ based on their virtual identity with other formulations.
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This is one of the promising findings regarding this 
new device. However, to reach the clinical trial step, 
the device must be more thoroughly tested in the pre-
clinical phase. Before the test phase is initiated, clini-
cal data are required for long-term safety, evaluation 
of distal embolisation, pharmacokinetics and casing 
inflation to verify toxicity. After the test phase of this 
new drug-eluting balloon is finished, including clinical 
trials, a drug known to drug-eluting stents, sirolimus, 
may become a new option for drug-eluting balloons, 
and this new coating technology with nanoparticles 
may become an advancement regarding drug-eluting 
methods in cardiovascular intervention.
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